Innovative Neurotechnology Cognision's FDA-cleared COGNISION® system and its integrated platform Cognision360™ offer advanced neurocognitive biomarkers and assessment tools that are highly valuable for pharmaceutical companies and clinical researchers focusing on CNS drug development and neurodegenerative disorders.

Recent Platform Launch The recent launch of Cognision360™ consolidates neurobiomarker data streams into a streamlined, standardized system, providing a compelling solution for organizations seeking to enhance data integration and streamline clinical trial workflows in neuroscience research.

Market Expansion Potential With a growing footprint in clinical trials and neurodiagnostic evaluations, Cognision is positioned to expand its reach within biotech and pharmaceutical markets focused on dementia, concussion, and other neurocognitive disorders, offering scalable technology solutions.

Strategic Partnerships As a founding member of the EEG/ERP Biomarker Qualification Consortium, Cognision has established strategic collaborations that could facilitate co-marketing, data validation, and funding opportunities to accelerate product adoption and increase market penetration.

Growth and Funding Opportunities Despite currently reporting revenue between 1M and 10M, Cognision's recent innovations and platform launches present strong sales opportunities with biotech and pharma firms investing in neurotechnology and CNS biomarkers, especially in the context of increasing clinical trial activity.